Ask Lazlo

life sciences… only

Robert Nelsen: ARCH Venture Partners, Managing Director

Robert NelsenCompany: Arch Venture Partners

Position: Co-founder and Managing Director

Bio (from http://www.archventure.com/directors.html)

Robert Nelsen is a co-founder and a Managing Director of ARCH Venture Partners.

Mr. Nelsen joined ARCH at its founding and has played a significant role in the early sourcing, financing and development of more than thirty companies including Sapphire Energy, Ikaria, Illumina (ILMN), Adolor (ADLR), Aviron (AVIR, acquired by Medimmune-MEDI), Caliper Life Sciences (CALP), Trubion Pharmaceuticals (TRBN), Array BioPharma (ARRY), NetBot, deCODE Genetics (DCGN), Nanosys, Alnylam Pharmaceuticals (ALNY), XenoPort (XNPT), GenVec (GNVC), R2 Technology (acquired by Hologic-HOLX), IDUN Pharmaceuticals (acquired by Pfizer-PFE), Genomica (GNOM, acquired by Exelixis-EXEL), Surface Logix, NeurogesX (NGSX), Classmates.com (acquired by United Online-UNTD), Nura (acquired by Omeros), Kythera Biopharmaceuticals, Elixir Pharmaceuticals, Spaltudaq, VLST, Ensemble Discovery, Accelerator, Apoptos, Fate Therapeutics, Agios Pharmaceuticals, and Everyday Learning.

Mr. Nelsen is a director of Ikaria, Sapphire Energy, Fate Therapeutics, Agios Pharmaceuticals, NeurogesX, and Kythera Biopharmaceuticals. He previously serves on the boards of Trubion Pharmaceuticals, Surface Logix, Adolor, NetBot, Everyday Learning, Spaltudaq, Array BioPharma, Caliper Life Sciences, Illumina, R2 Technology, and Classmates.com, among others. He also serves as a director of the Fred Hutchinson Cancer Research Institute. Mr. Nelsen holds an M.B.A. from The University of Chicago and a B.S. in Economics and Biology from the University of Puget Sound.

Advertisements

November 28, 2008 Posted by | Profiles, Venture Capital | , , , , | Leave a comment